Navigation Links
Ascenta Therapeutics Announces Results of Preclinical Evaluation of AT-406 in Multiple Cancer Models
Date:4/21/2009

- Data on novel pro-apoptotic agent presented at the 100th Annual Meeting of the American Association for Cancer Research -

- University of Pennsylvania data on chemotherapy resistance patterns in neuroblastoma cell lines, highlighting AT-101's inhibition of Mcl-1, also presented -

MALVERN, Pa., April 21 /PRNewswire/ -- Ascenta Therapeutics announced today that the results of preclinical studies of its orally-active, small molecule, pro-apoptotic agent, AT-406, have been presented at the 100th Annual Meeting of the American Association for Cancer Research (AACR), in Denver, Colorado (Abstract # 1917).

(Logo: http://www.newscom.com/cgi-bin/prnh/20090227/PH75873LOGO )

The studies demonstrated that AT-406 was active as a single agent in vitro in a number of cell lines, including breast cancer, lung cancer, pancreatic cancer, prostate cancer, and bladder cancer, and in several mouse xenograft cancer models. AT-406 also showed synergistic or additive effects when used together with tyrosine kinase inhibitors or chemotherapy in vitro in those cell lines.

"AT-406 is the second agent in our development pipeline to demonstrate broad anti-cancer activity in pre-clinical models, including synergy with other agents, by targeting a specific apoptotic pathway," said Mel Sorensen, MD, CEO of Ascenta Therapeutics. "On the basis of these encouraging data, we plan to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration to allow us to begin human clinical trials with AT-406 later this year."

About AT-406

AT-406 is an orally-active, small molecule drug designed to promote programmed cell death (apoptosis) in tumor cells
'/>"/>

SOURCE Ascenta Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vantia Therapeutics Appoints Rachel Morten as Head of Regulatory Affairs
2. Quark Pharmaceuticals to Present at American Society for Pharmacology and Experimental Therapeutics Annual Meeting
3. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
4. Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals
5. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $15 Million of Preferred Stock
6. Tolera Therapeutics Granted Orphan Drug Designation for Organ Transplant Rejection Drug
7. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
8. Cell Therapeutics Satisfies NASDAQ Listing Requirements to Continue to Trade on NASDAQ Capital Market
9. TorreyPines Therapeutics Receives Notice of Non-Compliance with Nasdaq Continued Listing Requirements
10. Cornerstone Therapeutics to Present at BioCenturys 2009 Future Leaders in the Biotech Industry Conference
11. Arno Therapeutics Reports 2008 Year-End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Francisco, CA (PRWEB) July 10, 2014 ... family closer together. The Archer Family purchased a ... contained within DNA, but ended up with a lifetime ... discoveries contained within the family members’ DNA genuinely brought ... had decided to search deeper into genetic history and ...
(Date:7/10/2014)... POINT, Ind. , July 10, 2014 ... expanded its use of capnography for respiratory ... growing group of healthcare leaders in embracing ... measures how effectively patients are breathing and ... depression occurs. By measuring the amount of ...
(Date:7/10/2014)... --  Ceres, Inc . (Nasdaq: CERE ), ... results for the three months ended May 31, 2014 ... Ceres reported that the company and its customers have ... in Brazil, which concluded in June, despite dry and ... for part of the growing season. Yields of several ...
(Date:7/10/2014)... psychiatric disorders has been extremely challenging because there are ... insufficient to cause disease. Now investigators reporting in the ... Cell Stem Cell describe a strategy that may ... other risk factors or environmental exposures to affect the ... genetic variant that may predispose individuals to schizophrenia. ...
Breaking Biology Technology:Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9New strategy could uncover genes at the root of psychiatric illnesses 2
... 15 3SBio Inc. (Nasdaq:,SSRX), a leading China-based ... biopharmaceutical products, today,announced the results of the shareholder ... held on September 12, 2008 (Friday) at 10:00 ... shareholders re-elected Dr. Jing Lou,Liping Xu, Bin Huang, ...
... Plans to Phase in Routine Vaccination Program ... and Young Children -, COLLEGEVILLE, Pa., Sept. ... WYE ), today announced that,South Africa has ... (Pneumococcal Saccharide Conjugated Vaccine,Adsorbed), a vaccine which helps ...
... Biopharma,Inc. (OTC Bulletin Board: CBPC) announced today that it ... of Delaware an amendment to its Certificate,of Incorporation to ... common stock ("Common Stock") will begin trading on a,reverse-split ... CHBO., By unanimous written consent dated July 3, ...
Cached Biology Technology:South Africa Begins Introduction of PREVENAR into Childhood Immunization Program 2South Africa Begins Introduction of PREVENAR into Childhood Immunization Program 3South Africa Begins Introduction of PREVENAR into Childhood Immunization Program 4China Biopharma Effects 1 for 100 Reverse Stock Split 2China Biopharma Effects 1 for 100 Reverse Stock Split 3
(Date:7/11/2014)... City of Entiat on Tuesday, July 8, 2014. Despite ... to over 1,000 acres by evening. Three outbuildings were ... by the Washington Department of Natural Resources. The ... developing fire control strategies and tactics. Other cooperators include ... Natural Resources, (WA DNR), Bureau of Land Management, Chelan ...
(Date:7/11/2014)... of Standards and Technology (NIST) need a special ... often prove that necessity is truly the mother ... M. Lorna De Leoz and Stephen Stein, NIST ... Glycomics is the study of the abundant, often-branched ... proteins and lipids and influence cellular processes, including ...
(Date:7/11/2014)... University, Sweden, have explored two different ways that ... leading to the formation of oxygen molecules in ... the scientific journal Nature Communications . , ... synthetic catalysts for water oxidation, which are key ... direct storage of solar energy in fuels like ...
Breaking Biology News(10 mins):Molecular snapshots of oxygen formation in photosynthesis 2
... exposed to low doses of atrazine, a widely used herbicide, ... through puberty later than non-exposed animals. The research adds to ... used to control weeds and grasses in crops such as ... to be relatively persistent in the environment, potentially finding their ...
... current issue of Deutsches rzteblatt International (Dtsch ... pharmacologist, and coauthors present the PRISCUS List: a list ... effects when given to elderly patients. The authors ... Germany in the setting of a joint project entitled ...
... Chinese on EurekAlert! Chinese . ... Medicine, Hershey, Pennsylvania have discovered that the Opioid Growth ... important system with potent antitumor properties, has controlled entry ... passage of OGF-OGFr is critical to cell proliferation and ...
Cached Biology News:Atrazine causes prostate inflammation in male rats and delays puberty 2Regulation of cell proliferation is dependent on nucleocytoplasmic trafficking 2Regulation of cell proliferation is dependent on nucleocytoplasmic trafficking 3